CCR4 and pancreatic neoplasm: In a phase I study of nivolumab plus mogamulizumab, a monoclonal antibody targeting CCR4, for patients with solid tumors, the partial response, and stable disease rates in 15 patients with pancreatic cancer were 7% and 33%, respectively [59].